Citations

Showing 10 of 108119 citations.

Glial Fibrillary Acidic Protein Immunoglobulin G in CSF
McKeon, Andrew, McKeon, Andrew

Mayo Clinic

Neurology | November 19, 2021 | Volume: 98 | Issue: 6 | Pages: 221-222

10.1212/wnl.0000000000013089 | PMID 34799465 Get It

Clinical Reasoning: A 31-Year-Old Man With Sequential Vision Loss
Fortes, Blake, Chen, John J., Bhatti, M. Tariq, Chen, John J. , Fortes, Blake H. , Chen, John J , Fortes, Blake H , Chen, John J., Bhatti, M. Tariq

Mayo Clinic

Neurology | November 19, 2021 | Volume: 98 | Issue: 4 | Pages: 163-169

10.1212/wnl.0000000000013084 | PMID 34799463 Get It

Centers for Medicare & Medicaid Services Price Publication Requirement: If You Post It, Will They Come?
Cowart, Jennifer B. , Dutta, Suparna

Mayo Clinic

Journal of Hospital Medicine | November 19, 2021 | Volume: 16 | Issue: 11 | Pages: 704-704

10.12788/jhm.3708 | PMID 34752216 Get It

Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI
Zara, Pietro , Floris, Valentina , López‐Chiriboga, A. Sebastian , Solla, Paolo , Sechi, Elia , Flanagan, E P , Lopez-Chiriboga, A Sebastian , Sechi, Elia , Flanagan, Eoin P. , Weinshenker, Brian G.

Mayo Clinic

Multiple Sclerosis Journal - Experimental, Translational and Clinical | November 19, 2021 | Volume: 7 | Issue: 4 | Pages: No page available

10.1177/20552173211048761 | PMID 34820135 Get It

Background Myelin-oligodendrocyte-glycoprotein (MOG)-IgG-positivity in patients with typical MS lesions on MRI may lead to diagnostic/therapeutic uncertainty. Objective and Methods We reviewed reports of cases with MS phenotype on MRI and MOG-IgG-positivity published in Pubmed between 01/2012–06/2021. Results Sixteen patients were included (median age [range], 37,5 [25–66] years; 60% female). Three patients initially tested negative for MOG-IgG. Disease course was: relapsing-remitting, 10; or progressive, 6. Intrathecal IgG-synthesis was common (79%). Low and high-efficacy MS-targeted agents prevented relapses in 30% and 100%, respectively. None of the patients showed resolution of MRI T2-lesions over time. Conclusions MOG-IgG-positivity is unlikely to alter the expected treatment response and outcomes in patients with otherwise typical MS phenotype on MRI.
De novo PBX1 variant in a patient with glaucoma, kidney anomalies, and developmental delay: An expansion of the CAKUTHED phenotype
Safgren, Stephanie L. , Olson, Rory J. , Bothun, Erick D. , Hanna, Christian , Klee, Eric W. , Schimmenti, Lisa A. , Vairo, Filippo , Bothun, Erick D , Hanna, Christian , Klee, Eric W , Schimmenti, Lisa A , Safgren, Stephanie L , Olson, Rory , Vairo, Filippo Pinto e

Mayo Clinic

American Journal of Medical Genetics Part A | November 19, 2021 | Volume: 188 | Issue: 3 | Pages: 919-925

10.1002/ajmg.a.62576 | PMID 34797033 Get It

AbstractAn infant was referred for evaluation of congenital glaucoma and corneal clouding. In addition, he had a pelvic kidney, hypotonia, patent ductus arteriosus, abnormal pinnae, and developmental delay. Exome sequencing identified a previously unpublished de novo single nucleotide insertion in PBX1 c.400dupG (NM_002585.3), predicted to cause a frameshift resulting in a truncated protein with loss of function (p.Ala134Glyfs*65). Identification of this loss of function variant supports the diagnosis of congenital anomalies of the kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay (CAKUTHED). Here, we propose glaucoma as an extra‐renal manifestation associated with PBX1‐related disease due to the relationship of PBX1 with MEIS1, MEIS2, and FOXC1 transcription factors associated with eye development.
Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis
Ma, Christopher , Feagan, Brian G. , Guizzetti, Leonardo , Zou, Guangyong , McFarlane, Stefanie C., Shackelton, Lisa M. , Hirano, Ikuo , Rooij, Willemijn E. de , Pai, Rish K. , Dellon, Evan S. , Ma, C , Guizzetti, L , Zou, Guangyong , Jairath, Vipul , Collins, Margaret H. , Schaeffer, David F. , Bredenoord, Albert J.

Mayo Clinic

American Journal of Gastroenterology | November 19, 2021 | Volume: 117 | Issue: 2 | Pages: 264-271

10.14309/ajg.0000000000001571 | PMID 34797816 Get It

INTRODUCTION: The optimal instrument for assessing histologic disease activity in patients with eosinophilic esophagitis (EoE) is unclear. We assessed the responsiveness of the EoE Histologic Scoring System (EoE-HSS) when compared with that of the peak eosinophil count (PEC). METHODS: Histopathology slides were obtained from patients with EoE at baseline and after 8 weeks of treatment with swallowed topical budesonide or elimination diet. Two blinded gastrointestinal pathologists scored biopsies on the EoE-HSS, PEC, and 100-mm visual analog scale (VAS) of overall histologic severity. Change was defined as an improvement by ≥0.5 SD in baseline VAS. Responsiveness was quantified using the standardized effect size (SES) and the probability that the index distinguishes a patient with improvement from a patient without improvement, which is the area under the receiver operating characteristic curve (AUC). Longitudinal validity was assessed using Pearson correlations between changes in EoE-HSS and both PEC and VAS. RESULTS: The EoE-HSS grade (SES 2.18 [95% confidence interval, CI: 1.46–2.88]; AUC 0.73 [95% CI: 0.57–0.84]) and stage (SES 2.07 [95% CI: 1.37–2.77]; AUC 0.73 [95% CI: 0.58–0.84]) were highly responsive, similar to PEC (SES 1.44 [95% CI: 0.80–2.07]; AUC 0.73 [95% CI: 0.58–0.84]). The EoE-HSS grade and stage were more highly correlated with changes in VAS (grade 0.92 [95% CI: 0.86–0.95]; stage 0.89 [95% CI: 0.81–0.94]) than with changes in PEC (grade 0.74 [95% CI: 0.58–0.85]; stage 0.66 [95% CI: 0.47–0.80]). DISCUSSION: The EoE-HSS is highly responsive, performs similarly to PEC, and is better correlated with changes in overall histologic activity in patients with EoE.
Plasma IL-2 and Symptoms Response after Acute Gluten Exposure in Subjects With Celiac Disease or Nonceliac Gluten Sensitivity
Cartee, Amanda K. , Choung, Rok Seon , Wang, Suyue , Dyke, Carol T. Van, Hinson, Chadrick A., Marietta, Eric, Katzka, David A. , Nehra, Vandana, Grover, Madhusudan , King, Katherine S. , Van Dyke, Carol T, Dzuris, John L. , Anderson, Robert P. , Murray, Joseph A. , Choung, Rok Seon

Mayo Clinic

American Journal of Gastroenterology | November 19, 2021 | Volume: 117 | Issue: 2 | Pages: 319-326

10.14309/ajg.0000000000001565 | PMID 34797778 Get It

INTRODUCTION: Treated patients with celiac disease (CeD) and nonceliac gluten sensitivity (NCGS) report acute, transient, incompletely understood symptoms after suspected gluten exposure. To determine whether (i) blinded gluten exposure induces symptoms, (ii) subjects accurately identify gluten exposure, and (iii) serum interleukin-2 (IL-2) levels distinguish CeD from NCGS subjects after gluten exposure. METHODS: Sixty subjects (n = 20 treated, healed CeD; n = 20 treated NCGS; n = 20 controls) were block randomized to a single, double-blind sham (rice flour) or 3-g gluten challenge with 72-hours follow-up. Twelve serial questionnaires (100 mm visual analog scale; pain, bloating, nausea, and fatigue) and 10 serial plasma samples were collected. Mucosal permeability was assessed using both urinary lactulose- 13 C mannitol ratios and endoscopic mucosal impedance. RESULTS: Thirty-five of 40 (83%) subjects with CeD and NCGS reported symptoms with gluten (8 CeD, 9 NCGS) and sham (9 CeD, 9 NCGS) compared with 9 of 20 (45%) controls after gluten (n = 6) and sham (n = 3). There was no significant difference in symptoms among groups. Only 2 of 10 subjects with CeD and 4 of 10 NCGS identified gluten, whereas 8 of 10 subjects with CeD and 5 of 10 NCGS identified sham. A significant plasma IL-2 increase occurred only in subjects with CeD after gluten, peaking at 3 hours and normalizing within 24 hours postchallenge despite no significant intestinal permeability change from baseline. DISCUSSION: Symptoms do not reliably indicate gluten exposure in either subjects with CeD or NCGS. IL-2 production indicates a rapid-onset gluten-induced T-cell activation in CeD despite long-standing treatment. The effector site is unknown, given no increased intestinal permeability after gluten.
Neurofibromatosis 1 in the setting of dual diagnosis: Diagnostic and management conundrums
Muthusamy, Karthik , El‐Jabali, Aseel, Ongie, Laura , Dhamija, Radhika , Babovic‐Vuksanovic, Dusica , Muthusamy, Karthik , Dhamija, Radhika

Mayo Clinic

American Journal of Medical Genetics Part A | November 19, 2021 | Volume: 188 | Issue: 3 | Pages: 911-918

10.1002/ajmg.a.62575 | PMID 34797032 Get It

AbstractNeurofibromatosis type 1 (NF1) is a common neurocutaneous disorder characterized by development of pigmentary skin changes, neurogenic tumors, and other manifestations involving multiple organ systems. Penetrance is complete, though expressivity is quite variable even among the family members. Given that NF1 is a common hereditary condition, existence of a second genetic disorder in NF1 patients is not unexpected. During comprehensive evaluations of individuals with NF1, we encountered 11 patients with dual diagnosis who contributed to phenotypic complexity and challenges for long‐term management. Examples include Prader–Willi Syndrome, Autosomal Dominant Polycystic Kidney Disease, Down syndrome, infantile myofibromatosis, Craniosynostosis, cleft lip and palate, 47,XYY, 22q11.2 duplication, 15q13.3 deletion syndrome, and BRCA2‐ and ATM‐ related cancer predisposition syndromes. Presence of dysmorphism, developmental delay, atypical tumors, and family history of other genetic disorders including cancers appears as determinants to consider a second genetic etiology and helps to differentiate from an extreme phenotypic spectrum of NF1. Clinicians should have high index of suspicion to exclude coexisting disorders, as apart from providing comprehensive medical care. This also has potential implications in genetic counseling. Long‐term effects of the synergistic mechanisms leading to phenotypic complexity and patient outcomes are yet to be characterized, with follow‐up needed.
Faculty Opinions recommendation of Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort.
Ansell, Stephen M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 19, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.741131181.793589731 Get It

Association of Preoperative Chemosensitivity With Postoperative Survival in Patients With Resected Gastric Adenocarcinoma
Deng, Lei , Groman, Adrienne , Jiang, Changchuan , Perimbeti, Stuthi, Gabriel, Emmanuel , Kukar, Moshim , Mukherjee, Sarbajit , Gabriel, Emmanuel M , Deng, Lei

Mayo Clinic

JAMA Network Open | November 19, 2021 | Volume: 4 | Issue: 11 | Pages: e2135340

10.1001/jamanetworkopen.2021.35340 | PMID 34797369 Get It